ARTES Biotechnology joins TA101 GOCLIN

A lead­ing con­sor­tium of indus­tri­al part­ners has been award­ed a grant by the Sev­enth Frame­work Pro­gram of the Euro­pean Union for an inno­v­a­tive research and devel­op­ment project “TA101 GOCLIN: Clin­i­cal devel­op­ment of TA-101 for the treat­ment of rheuma­toid arthri­tis“ (#606352). The aim of this Project is to take TA101, a small domain anti­body devel­oped by TechnoPhage, into the clin­i­cal stage of devel­op­ment for rheuma­toid arthri­tis (RA) and devel­op a nov­el mode of admin­is­tra­tion for the mar­ket of bio­log­ic ther­a­peu­tics. The project is fore­cast­ed for com­ple­tion in 2015, with a total dura­tion of 26 months. The total bud­get is EUR 1,72 mil­lion cor­re­spond­ing to a total Euro­pean fund­ing of EUR 1,36 million.

TA101 GOCLIN has mobi­lized the crit­i­cal mass of sev­en indus­tri­al part­ners from 5 Euro­pean coun­tries. These part­ners are from Bel­gium, France, Ger­many, The Nether­lands and Portugal.

Amspar B.V will design and devel­op an inte­grat­ed micronee­dle patch com­bi­na­tion loaded with TA_101. In this regard, Amspar will close­ly work togeth­er with Lab­o­ra­toires Plas­to San­té (expert in phar­ma­ceu­ti­cal patch devel­op­ment) and Micro­Cre­ate BV (micronee­dle array manufacturing).
Q‑Biologicals NV togeth­er with ARTES Biotech­nol­o­gy GmbH will devel­op a suit­able micro­bial expres­sion host and man­u­fac­tur­ing process. cGMP mate­r­i­al for clin­i­cal tri­als will be pro­duced by Q‑Biologicals.
Clin­i­cal tri­als will be con­duct­ed by SGS Life Sci­ence Services.